Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine (Q41123069)

27 September 2017

title

Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine (English)

1 reference

27 September 2017

1 reference

Chong KT

1

1 reference

27 September 2017

Pagano PJ

series ordinal

2

1 reference

27 September 2017

publication date

1 March 1997

1 reference

27 September 2017

1 reference

27 September 2017

volume

34

1 reference

27 September 2017

issue

1

1 reference

27 September 2017

page(s)

51-63

1 reference

Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

Genomic variation of human immunodeficiency virus type 1 (HIV-1): molecular analyses of HIV-1 in sequential blood samples and various organs obtained at autopsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

1 reference

7 January 2021

Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

Multiple drug effect analysis with confidence interval

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

Combination therapy for infection due to human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

HIV resistance to reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

Consensus symposium on combined antiviral therapy. International Society for Antiviral Research and the National Institutes of Allergy and Infectious Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

Combination therapy: more effective control of HIV type 1?

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

The implications of drug resistance for strategies of combination antiviral chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

Isolation frequency and growth properties of HIV-variants: multiple simultaneous variants in a patient demonstrated by molecular cloning.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-3542%2896%2901021-2

7 January 2021

10.1016/S0166-3542(96)01021-2

Identifiers

DOI

1 reference

27 September 2017

1 reference